Abstract
Renal failure is a common clinical feature in multiple myeloma (MM). The overall remission rate is 35 %-50% (complete remission is rare) in MM patients with renal failure treated by conventional chemotherapy. Many centers use high dose chemotherapy and autologous stem cell transplantation (ASCT) for the treatment of MM patients with renal failure. The current study showed that the severity of renal function damage and dialysis had no impact on stem cell mobilization and implantation. High dose melphalan and ASCT could increase the rates of complete remission, event free survival and overall survival to 30 %, about 20 and 40 months longer, respectively and some patients discontinued dialysis. However there are many problems in this area, such as a higher treatment related mortality leaded by APBSCT. In addition, the role of new agents, such as thalidomide, bortezomib and lenalidomide, require evaluation in MM patient with renal failure. Key words: Multiple myeloma; Autologous; Stem cell transplantation; Kidney failure
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
